CVRx, Inc.
About CVRx, Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $56.7M
- Net income
- -$53.3M
- Total assets
- $104.8M
- Market cap
- $142.8M
- Gross margin
- 85.3%
- Operating margin
- -90.5%
- Net margin
- -94.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $56.7M
- Cost of revenue
- $8.3M
- Gross profit
- $48.3M
- Operating expenses
- $99.6M
- Operating income
- -$51.3M
- Income tax
- -$18.0K
- Net income
- -$53.3M
- EPS (basic)
- $-2.04
- EPS (diluted)
- $-2.04
Balance sheet
- Total assets
- $104.8M
- Current assets
- $101.6M
- Total liabilities
- $65.5M
- Current liabilities
- $13.3M
- Shareholders’ equity
- $39.3M
Cash flow
- Operating cash flow
- -$40.2M
- Investing cash flow
- -$580.0K
- Financing cash flow
- $10.5M
- Net cash flow
- -$30.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $142.8M
- EPS (diluted)
- $-2.04
- Shares outstanding
- 26.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 30, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $53.3M in FY2025.
- Revenue grew 335% from FY2021 to FY2025.
- Gross margin of 85.3%, net margin -94.1%.
- Trading 50% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CVRx, Inc..
Write a review
News about CVRx, Inc.
News & sentiment via Polygon.io
